Cadila Healthcare’s subsidiary Zydus Pharmaceuticals (USA) Inc., a leading generic pharmaceutical company in the United States, has settled the patent litigation relating to Aptalis’s CANASA (mesalamine suppository, 1 g). As a result of the settlement, Zydus Pharmaceuticals (USA) Inc., will be able to market its generic version of CANASA in the United States beginning on June 13, 2019, or earlier under certain circumstances.
Zydus Cadila previously received tentative approval from the USFDA to market its generic version of CANASA (mesalamine suppository, 1 g). CANASA is indicated to treat mildly to moderately active ulcerative colitis. Zydus Cadila’s generic product will be produced at the group’s Topical plant at Ahmedabad.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: